Sector
PharmaceuticalsOpen
₹578.95Prev. Close
₹574.1Turnover(Lac.)
₹365.16Day's High
₹579.1Day's Low
₹55552 Week's High
₹979.552 Week's Low
₹499Book Value
₹331.31Face Value
₹10Mkt Cap (₹ Cr.)
1,131.88P/E
12.88EPS
44.62Divi. Yield
0.31Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
---|---|---|---|---|
Equity Capital | 20.03 | 20.03 | 20.03 | 20.03 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 572.81 | 482.44 | 412.85 | 346.36 |
Net Worth | 592.84 | 502.47 | 432.88 | 366.39 |
Minority Interest |
Y/e 31 Mar( In .Cr) | Mar-2020 | Mar-2018 | Mar-2017 | Mar-2016 |
---|---|---|---|---|
Revenue | 376.08 | 324.95 | 304.27 | 310.81 |
yoy growth (%) | 15.73 | 6.79 | -2.1 | 39.21 |
Raw materials | -186.77 | -171.16 | -172.67 | -203.65 |
As % of sales | 49.66 | 52.67 | 56.74 | 65.52 |
Employee costs | -54.89 | -47.5 | -35.05 | -26.73 |
Y/e 31 Mar( In .Cr) | Mar-2020 | Mar-2018 | Mar-2017 | Mar-2016 |
---|---|---|---|---|
Profit before tax | 64.04 | 43.09 | 35.74 | 30.05 |
Depreciation | -5.46 | -4.39 | -3.85 | -3.21 |
Tax paid | -14.48 | -10.34 | -8.33 | -8.31 |
Working capital | -8.51 | 25.15 | 13.34 | -4.84 |
Other operating items |
Y/e 31 Mar | Mar-2020 | Mar-2018 | Mar-2017 | Mar-2016 |
---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 15.73 | 6.79 | -2.1 | 39.21 |
Op profit growth | 29.17 | 8 | 30.85 | 40.73 |
EBIT growth | 39.41 | 15.08 | 15.61 | 39.5 |
Net profit growth | 51.3 | 19.53 | 26.01 | 47.2 |
Particulars (Rupees in Crores.) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
---|---|---|---|---|---|
Gross Sales | 580.55 | 510.31 | 472.12 | 424.19 | 386.49 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 580.55 | 510.31 | 472.12 | 424.19 | 386.49 |
Other Operating Income | 0 | 0 | 0 | 0 | 0 |
Other Income | 34.42 | 22.47 | 10 | 5.66 | 11.04 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,709.35 | 130.19 | 4,10,142.32 | 1,181.05 | 0.79 | 5,985.33 | 98.33 |
Divis Laboratories Ltd DIVISLAB | 5,482.85 | 70.31 | 1,45,762.16 | 594 | 0.55 | 2,297 | 513.62 |
Cipla Ltd CIPLA | 1,415.25 | 24.56 | 1,14,322.24 | 1,438.15 | 0.92 | 4,134.87 | 360.73 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,286.5 | 60.94 | 1,11,165.87 | 485 | 0.85 | 2,330 | 222.38 |
Mankind Pharma Ltd MANKIND | 2,451.2 | 52.28 | 1,01,098.24 | 416.38 | 0 | 2,396.57 | 334.17 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairman (Non-Executive)
Kishorbhai M Shah
Managing Director
Mahendra G Patel
Whole-time Director
Hasmukhbhai I Patel
Whole-time Director
Munjal Mahendrabhai Patel
Whole-time Director
Aashish R Patel
Independent Director
Saurin J Parikh
Non Executive Director
Rajnikant G Patel
Company Sec. & Compli. Officer
Trusha Shah
Independent Director
Seema Mehta
Independent Director
Nareshkumar Pirabhai Suthar
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Lincoln Pharmaceuticals Ltd
Summary
Lincoln Pharmaceuticals Limited, promoted by Mahendra G Patel, Rajnikant G Patel and Hasmukhbhai I Patel, as a Partnership Firm in January, 1979 to manufacture pharmaceutical formulations was converted into a Public Limited Company in Jan. 95. All the assets and business of the erstwhile partnership were transferred to the Company. The Company is engaged in the business of manufacturing and trading of pharmaceutical products. The focused area includes anti-infective, respiratory system, gynecology, cardio & CNS, anti-diabetic, anti malaria, among others.The Company, incorporated in January, 1995, was carrying on its business by getting its products manufactured on loan licence basis from 1979 to 1982. It then set up its own manufacturing facilities at Naroda, Gujarat for manufacturing tablets, capsules, liquid and powder syrups and, ointments. It is also getting its products manufactured on loan licence basis from other manufacturers to meet the demand of small volume parenterals.The company has set up a modern formulation manufacturing plant at Khatraj (Mehsana district), Gujarat, to manufacture small volume parenterals like dry powder injectables, liquid vial, liquid ampoules and eye drops and expand its production capacities of the existing products. It is also in the process of establishing a fully equipped laboratory to undertake in-house testing of its products for better quality control and R&D. It came out with a public issue in Feb.96 to part-finance its project.The
Read More
The Lincoln Pharmaceuticals Ltd shares price on NATIONAL STOCK EXCHANGE (NSE) is ₹565.1 today.
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Lincoln Pharmaceuticals Ltd is ₹1131.88 Cr. as of 04 Apr ‘25
The PE and PB ratios of Lincoln Pharmaceuticals Ltd is 12.88 and 1.80 as of 04 Apr ‘25
The 52-week high/low is the highest and lowest price at which a Lincoln Pharmaceuticals Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Lincoln Pharmaceuticals Ltd is ₹499 and ₹979.5 as of 04 Apr ‘25
Lincoln Pharmaceuticals Ltd's CAGR for 5 Years at 36.79%, 3 Years at 20.06%, 1 Year at -5.96%, 6 Month at -14.93%, 3 Month at -32.82% and 1 Month at 6.02%.
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.